Evidence map›Paper›PMID 34249462›Full record

ArticleAmerican journal of cancer research2021

A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Robert F Cornell, Michael R Bishop, Shaji Kumar, Sergio A Giralt, Ajay K Nooka, Sarah M Larson, Frederick L Locke, Noopur S Raje, Lei Lei, Jinghui Dong and 3 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03318861 (A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma), which is not on this map. Cited by 13 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 5 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03318861 phase1terminatednot on this map

A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma

TypeinterventionalSponsorKite, A Gilead CompanyRan2017 to 2022Enrolled17ConditionsRelapsed/Refractory Multiple MyelomaArmsKITE-585, Cyclophosphamide, Fludarabine
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 5 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Introduction to "Immunotherapies for Multiple Myeloma".Pharmaceuticals (Basel, Switzerland) · 2020
    Article
  13. CAR T and CAR NK cells in multiple myeloma: Expanding the targets.Best practice & research. Clinical haematology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Robert F CornellVanderbilt University Medical Center Nashville, TN, USA.
Michael R BishopThe University of Chicago Medicine Chicago, IL, USA.
Shaji KumarMayo Clinic Rochester, MN, USA.
Sergio A GiraltMemorial Sloan Kettering Cancer Center NY, USA.
Ajay K NookaWinship Cancer Institute, Emory University School of Medicine Atlanta, GA, USA.
Sarah M LarsonUCLA Medical Center Santa Monica, CA, USA.
Frederick L LockeMoffitt Cancer Center Tampa, FL, USA.
Noopur S RajeMassachussetts General Hospital Cancer Center Boston, MA, USA.
Lei LeiKite, A Gilead Company Santa Monica, CA, USA.
Jinghui DongKite, A Gilead Company Santa Monica, CA, USA.
John B Le GallKite, A Gilead Company Santa Monica, CA, USA.
John M RossiKite, A Gilead Company Santa Monica, CA, USA.
Robert Z OrlowskiThe University of Texas MD Anderson Cancer Center Houston, TX, USA.
Emory University · USMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUCLA Medical Center · USVanderbilt University Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083
6 · The paper itself

Abstract

Despite advances in treatment, most patients with multiple myeloma (MM) will relapse, and long-term survival remains poor. B-cell maturation antigen (BCMA) is an ideal therapeutic target as it is expressed throughout the disease course with normal tissue expression limited to plasma and some B-cell lineages. This phase 1, multicenter, first-in-human study evaluated the safety and efficacy of KITE-585, an autologous anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory MM (RRMM). Key eligibility criteria included measurable MM and progression, defined by the International Myeloma Working Group Consensus Criteria within 60 days of the last treatment. Patients underwent leukapheresis and subsequently received a 3-day conditioning therapy regimen (cyclophosphamide [300 mg/m

Indexed as

B-cell maturation antigenChimeric antigen receptor T cellrelapsed/refractory multiple myeloma

Identifiers

PMID34249462
PMCPMC8263642
OpenAlexW3180740791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.